REG - Kromek Group PLC - Cancellation of £1.2m of Convertible Loan Notes

KromekAnnouncement

12/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240212:nRSL7874Ca&default-theme=true

RNS Number : 7874C  Kromek Group PLC  12 February 2024

12 February 2024

 

Kromek Group plc

("Kromek" or the "Company" or the "Group")

 

Cancellation of £1.2m of Convertible Loan Notes

 

and

 

Notice of General Meeting

 

 

Kromek Group plc (AIM: KMK), a leading developer of radiation and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments, announces that further to the announcement of 5 February 2024, in
which the Company announced a conversion of Loan Notes and accrued interest
(the "Loan Notes") by two Loan Note holders and the consequential admission of
23,639,520 ordinary shares of 1 penny each ("Ordinary Shares") in the Company
(the "Conversion"), the Company has since agreed to allot new Ordinary Shares
to another two Loan Note Holders in consideration of them cancelling their
Loan Notes that were due to expire later this month.

 

The two further Loan Note holders will cancel their Loan Notes, which total
£1.2m of debt, including accrued interest, and the Company has agreed to
conditionally allot 16,532,894 new Ordinary Shares (the "New Ordinary Shares")
in consideration of the two Loan Notes being cancelled (the "Cancellation").
This is being done at an effective price of 7.5 pence per Ordinary Share.

 

Following the Cancellation, the Company will only have £34,000 of outstanding
Loan Notes.

 

Following the allotment and admission of the 23,639,520 Ordinary Shares
pursuant to the Conversion, the Company does not have sufficient remaining
authorities to allot the New Ordinary Shares pursuant to the Cancellation.
Therefore the Cancellation is conditional, inter alia, upon Shareholders
approving resolutions at a general meeting that will grant to the Directors
the authority to allot the New Ordinary Shares and the power to disapply
statutory pre-emption rights in respect of the New Ordinary Shares (the
"Resolutions"). A general meeting is to be held at Kromek, NETPark, Thomas
Wright Way, Sedgefield, TS21 3FD at 10:00am on 4 March 2024 (the "General
Meeting"), where the Resolutions will be proposed.

 

In addition, the Company has agreed to allot 600,000 new Ordinary Shares in
lieu of professional fees due ("Fee Shares").

 

Application will be made to the London Stock Exchange for the New Ordinary
Shares and Fee Shares to be admitted to trading on AIM ("Admission") and it is
expected that Admission will become effective and that dealings in the New
Ordinary Shares and Fee Shares will commence at 8.00 a.m. on or around 5 March
2024 (being the business day following the General Meeting).

 

The new Ordinary Shares will rank pari passu with the existing shares of the
Company. Following Admission, the Company's issued share capital will consist
of 641,019,234 Ordinary Shares, none of which are held in treasury.
Accordingly, the figure of 641,019,234 may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

The Company intends to publish and send a shareholder circular and notice of
General Meeting (the "Circular") to Shareholders in connection with the
Resolutions on or around 14 February 2024. The Circular will be available from
the Company's website (https://www.kromek.com/investor-relations/
(https://www.kromek.com/investor-relations/) ) once published.

 

 

For further information, please contact:

  

Kromek Group plc
 Arnab Basu, CEO                                                        +44 (0)1740 626 060

 Paul Farquhar, CFO

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)        
 Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance            +44 (0)20 7220 0500

 Tim Redfern - ECM

 Michael Johnson/Tamar Cranford-Smith - Sales

 Gracechurch Group (Financial PR)
 Harry Chathli/Claire Norbury/Henry Gamble                              +44 (0)20 4582 3500

 

 

Kromek Group plc

 

Kromek Group plc is a leading developer of radiation detection and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments. Headquartered in County Durham, UK, Kromek has manufacturing
operations in the UK and US, delivering on the vision of enhancing the quality
of life through innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT),
security and industrial markets. Kromek provides its OEM customers with
detector components, based on its core cadmium zinc telluride (CZT) platform,
to enable better detection of diseases such as cancer and Alzheimer's,
contamination in industrial manufacture and explosives in aviation
settings.

 

In CBRN detection, the Group provides nuclear radiation detection solutions to
the global homeland defence and security market. Kromek's compact, handheld,
high-performance radiation detectors, based on advanced scintillation and
solid-state readout technology, are primarily used to protect critical
infrastructure, events, personnel and urban environments from the threat of
'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection
segment. These consist of fully automated and autonomous systems to detect a
wide range of airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the
trading symbol 'KMK'.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFASLEELSELE